Heron Therapeutics Inc vs 3M Company — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while 3M Company trades at $168.09 (market cap $82.99B). The key difference: 3M Company is far larger — about 907.4× Heron Therapeutics Inc's market cap, and 3M Company pays a 1.96% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | MMM | |
|---|---|---|
Market Cap | $91.46M | $82.99B |
Sector | Health | Industrials |
52-Week High | $1.96 | $174.61 |
52-Week Low | $0.39 | $141.10 |
Enterprise Value | $189.36M | $91.39B |
Dividend Yield | — | 1.96% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
3M (MMM) trades at $159.98, up 0.09% on the day, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $2.14, exceeding the $1.98 estimate, and maintains a strong net income margin of 11.14%. Analysts are divided with a 48.49% buy rating, and the consensus price target is $149.75. Recent news highlights Q2 earnings expectations and new partnerships, such as the Airbus A220 supply agreement.
The outlook for MMM is mixed; earnings momentum and cost optimization support growth, but valuation ratios like a P/E of 30.8 suggest premium pricing. Risks include consumer segment weakness and debt levels. Upside depends on Q2 results meeting the $2.27 EPS forecast, while downside could stem from macroeconomic pressures.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →